Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209–249

Article  PubMed  Google Scholar 

Dolcetti R, De Re V,Canzonieri V (2018) Immunotherapy for Gastric Cancer: Time for a Personalized Approach? Int J Mol Sci 19(6)

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F (2020) Gastric cancer. Lancet. 396(10251):635–648

Article  CAS  PubMed  Google Scholar 

Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P et al (2016) Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14(10):1286-1312

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD et al (2015) PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 372(26):2509–20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357(6349):409–413

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP et al (2020) Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 38(1):1–10

Article  CAS  PubMed  Google Scholar 

Oaknin A, Gilbert L, Tinker A V, Brown J, Mathews C, Press J et al (2022) Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer 10(1)

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 398(10294):27–40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C et al (2022) Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(2):167-192

Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z et al (2017) Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 3(9):1197–1203

Article  PubMed  Google Scholar 

Sun J, Wang X, Zhang Z, Zeng Z, Ouyang S, Kang W (2021) The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. Front Oncol. 11:641304

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu Y, Ma X, Zhang Y, Zhang Y, Ying J, Zhang W et al (2019) Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer. J Cancer. 10(12):2754–2763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Taube JM, Pardoll DM (2020) Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367(6477)

Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M et al (2022) A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer. 25(3):619–628

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 3(5):436–43

Article  CAS  PubMed  PubMed Central  Google Scholar 

McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA et al (2020) Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 20(4):203–217

Article  CAS  PubMed  Google Scholar 

Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D et al (2022) Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer 10(3)

Li S, Yu W, Xie F, Luo H, Liu Z, Lv W et al (2023) Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 14(1):8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei J, Lu X, Liu Q, Fu Y, Liu S, Li L et al (2022) Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer Manag Res. 14:2007–2015

Article  PubMed  PubMed Central  Google Scholar 

Li S, Xu Q, Dai X, Zhang X, Huang M, Huang K et al (2022) Efficacy and toxicity of neoadjuvant immune checkpoint inhibitors in resectable gastric cancer: A meta-analysis and systematic review. 40(4_suppl):291-291

Guo H, Ding P, Sun C, Yang P, Tian Y, Liu Y et al (2022) Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. Front Oncol. 12:927781

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei J, Lu X, Liu Q, Fu Y, Liu S, Yang J et al (2021) SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma. 39(15_suppl):4040-4040

Wei J, Liu Q, Chen H, Zhang X, Zhao F, Fu Y et al (2022) Abstract 6176: CD56 dim+ immune infiltration and reprogrammed TMEs associated with response to neoadjuvant anti-PD-1 immunotherapy plus concurrent chemoradiotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma. Cancer Res 82(12_Supplement):6176-6176

Raufi AG, Lee S, May M, Portillo AD, Sender N, Ana SS et al (2022) Abstract CT009: Phase II trial of perioperative pembrolizumab plus capecitabine and oxaliplatin followed by adjuvant pembrolizumab for resectable gastric and gastroesophageal junction (GC/GEJ) adenocarcinoma. Cancer Res 82(12_Supplement):CT009-CT009

Tang ZQ, Wang Y, Liu D, Yu YY, Cui YH, Tang C et al (2021) 1385P Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615). Annals of Oncology. 32:S1049

Article  Google Scholar 

Tang Z, Wang Y, Liu D, Wang X, Xu C, Yu Y et al (2022) The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 13(1):6807

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ludford K, Raghav KPS, Murphy MAB, Fleming ND, Nelson DA, Lee MS et al (2021) Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. 39(15_suppl):2520-2520

Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND et al (2023) Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 41(12):2181–2190

Article  CAS  PubMed  Google Scholar 

André T, Tougeron D, Piessen G, de la Fouchardière C, Louvet C, Adenis A et al (2023) Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 41(2):255–265

Article  PubMed  Google Scholar 

Li S, Yu W, Xie F, Liu Z, Lv W, Shi D et al (2021) A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer. 39(15_suppl):4061-4061

Kennedy T, Shah MM, In H, Chuy JW, Moore DF, Kooby DA et al (2021) Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163). 39(15_suppl):e16111-e16111

Liu Y, Han G, Li H, Zhao Y, Zhuang J, Wang G et al (2020) Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma. 38(15_suppl):4536-4536

Tao K, Yin Y, Lin Y, Li W, Li R, Liu W et al (2022) Neoadjuvant PD-1 inhibitor tislelizumab combined with s-1 plus oxaliplatin in patients with local advanced gastric cancer or gastroesophageal junction adenocarcinoma: Interim results of a single-arm, phase II trial. 2022; 40(4_suppl):300–300

Yin Y, Lin Y, Yang M, Lv J, Liu J, Wu K et al (2022) Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial. Front Oncol. 12:959295

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun W, Saeed A, Al-Rajabi RMDT, Kasi A, Veeramachaneni NK, Al-Kasspooles MF et al (2022) A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach. 2022; 40(16_suppl):4047–4047

Comprehensive molecular characterization of gastric adenocarcinoma (2014) Nature. 513(7517):202–9

Article  Google Scholar 

Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS et al (2015) Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 21(5):449–56

Article  CAS  PubMed  Google Scholar 

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K et al (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 24(9):1449–1458

Article  CAS  PubMed  Google Scholar 

Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ et al (2017) Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat Commun. 8(1):1050

Article  PubMed  PubMed Central  Google Scholar 

Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE et al (2019) Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 37(35):3392–3400

Article  PubMed  Google Scholar 

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R (2021) The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell. 39(2):154–173

Article  CAS  PubMed  Google Scholar 

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 30(1):44–56

Article  CAS  PubMed  Google Scholar 

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB et al (2019) Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol. 5(8):1195–1204

Article  PubMed  PubMed Central  Google Scholar 

Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z et al (2021) Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg. 25(2):421–427

Article  PubMed  Google Scholar 

Fornarini G, Rebuzzi SE, Banna GL, Calabrò F, Scandurra G, De Giorgi U et al (2021) Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 6(3):100118

Article